Head to Head Comparison: Fulgent Genetics (FLGT) and OpGen (OPGN)

Fulgent Genetics (NASDAQ: FLGT) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

Earnings and Valuation

This table compares Fulgent Genetics and OpGen’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fulgent Genetics $18.73 million 3.77 -$2.51 million ($0.11) -35.91
OpGen $3.21 million 3.32 -$15.41 million ($9.78) -0.18

Fulgent Genetics has higher revenue and earnings than OpGen. Fulgent Genetics is trading at a lower price-to-earnings ratio than OpGen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fulgent Genetics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, OpGen has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

Insider and Institutional Ownership

7.8% of Fulgent Genetics shares are held by institutional investors. 58.8% of Fulgent Genetics shares are held by company insiders. Comparatively, 31.8% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares Fulgent Genetics and OpGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fulgent Genetics -26.57% -7.62% -7.22%
OpGen -409.83% -437.11% -152.04%

Analyst Ratings

This is a summary of recent recommendations and price targets for Fulgent Genetics and OpGen, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulgent Genetics 0 1 1 0 2.50
OpGen 0 0 2 0 3.00

Fulgent Genetics presently has a consensus target price of $6.00, indicating a potential upside of 51.90%. OpGen has a consensus target price of $9.00, indicating a potential upside of 402.79%. Given OpGen’s stronger consensus rating and higher possible upside, analysts clearly believe OpGen is more favorable than Fulgent Genetics.


Fulgent Genetics beats OpGen on 9 of the 13 factors compared between the two stocks.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

About OpGen

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply